Chimeric Antigen Receptor T-Cell Therapy–Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma

cardiotoxicity cytokine release syndrome heart failure lymphoma, non-Hodgkin receptors, chimeric antigen tisagenlecleucel A doptive cell therapy using chimeric antigen receptor (CAR) T cells augments the ability of the patient's immune system to recognize and destroy cancer cells. Genetically modified autologous T-cell agents that target CD-19, tisagenlecleucel and axicabtagene ciloleucel, are currently approved for the treatment of children with B-cell acute lymphocytic leukemia and adults with aggressive B-cell lymphoma. Cytokine release syndrome (CRS) is a frequent adverse effect of CAR T-cell therapy and has been associated with cardiotoxicity. In this study, we examined the incidence and impact of CAR T-cell therapy-associated cardiomyopathy.